Home > Financial Ratios > MANKIND PHARMA

MANKIND PHARMA
EV/Core EBITDA

    Back to All Ratios
MANKIND PHARMA is part of below Screeners ↓
Top Large Cap Stocks with Best Fundamentals
Best Quarterly Growth Large Cap Stocks
COMMUNITY POLL
for MANKIND PHARMA
Please provide your vote to see the results

MANKIND PHARMA Last 5 Year EV/Core EBITDA History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   EV/Core EBITDA(x) 30.2832.74-0.120.23-0.23

What is the latest EV/Core EBITDA ratio of MANKIND PHARMA ?

The latest EV/Core EBITDA ratio of MANKIND PHARMA is 30.28 based on Mar2025 Consolidated results.
Year EV/Core EBITDA
Mar202530.28
Mar202432.74
Mar2023-0.12
Mar20220.23
Mar2021-0.23

How is EV/Core EBITDA of MANKIND PHARMA Trending?

Years EV/Core EBITDA % Change
Mar2025 30.28
-7.51
Mar2024 32.74
Positive
Mar2023 -0.12
Negative
Mar2022 0.23
Positive
Mar2021 -0.23 -

Other Financial Ratios of MANKIND PHARMA


Compare EV/Core EBITDA ratio of peers of MANKIND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
MANKIND PHARMA ₹89,742.7 Cr 1.5% -2.8% -19.5% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹418,708.0 Cr -2.9% -1.8% -2.5% Stock Analytics
DIVIS LABORATORIES ₹171,975.0 Cr 2.1% 0.2% 9.1% Stock Analytics
TORRENT PHARMACEUTICALS ₹128,619.0 Cr 0.5% 2.2% 11.2% Stock Analytics
CIPLA ₹122,539.0 Cr 0.7% -0.8% 3.4% Stock Analytics
DR REDDYS LABORATORIES ₹106,741.0 Cr -0.1% 2.5% 2.5% Stock Analytics


MANKIND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
MANKIND PHARMA

1.5%

-2.8%

-19.5%

SENSEX

-0.4%

-0.3%

3.9%


You may also like the below Video Courses